Innovent Biologics Revenue

Pharmaceutical Manufacturing • Wuzhong District, Jiangsu, China • 501-1000 Employees

Innovent Biologics revenue & valuation

Annual revenue	$3,501,500,000
Revenue per employee	$4,209,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$11,204,600,000
Total funding	No funding

Key Contacts at Innovent Biologics

Michael Yu

Co-Founder, Chairman And Ceo

Wei Zhang

Senior Director, Franchise Lead And Portfolio Management

Jessica Ye

Associate Director - Channel Management

Yang Yu

Associate Director Clinical Operations

Shuaixiang Zhou

Senior Director, Protein Sciences, Drug Discovery

Bin Zhou

Executive Director, Corporate Strategy & Business Development

Guozheng Li

It Senior Director

Robert Pelham

Executive Director, Global Head Of Clinical Biomarkers And Companion Diagnostics

Manni Gui

Executive Director Marketing

Ronnie Ede

Executive Director Of The Board

Company overview

Headquarters	168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123, CN
Phone number	+8651269566088
Website	innoventbio.com
NAICS	3254
SIC	283
Keywords	Biosimilars, Monoclonal Antibodies, Novel Drugs, Biologics Manufacturing
Founded	2011
Employees	501-1000
Socials

Innovent Biologics Email Formats

Innovent Biologics uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@innoventbio.com), used 89.5% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@innoventbio.com	89.5%
{first initial}.{last name}	j.doe@innoventbio.com	8.6%
{first name}	john@innoventbio.com	1.9%

About Innovent Biologics

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.

Employees by Management Level

Total employees: 501-1000

Seniority

Employees

Entry

Manager

Director

Employees by Department

Innovent Biologics has 136 employees across 15 departments.

Departments

Number of employees

Funding Data

Innovent Biologics has never raised funding before.

Innovent Biologics Tech Stack

Discover the technologies and tools that power Innovent Biologics's digital infrastructure, from frameworks to analytics platforms.

Vue.js

JavaScript frameworks

Node.js

Programming languages

Nuxt.js

JavaScript frameworks

core-js

JavaScript libraries

Swiper

JavaScript libraries

Babel

Miscellaneous

Google Maps

Maps

Webpack

Miscellaneous

Frequently asked questions

Innovent Biologics is located in Wuzhong District, Jiangsu, CN.

You can reach Innovent Biologics at +8651269566088.

Innovent Biologics generates an estimated annual revenue of $3,501,415,044. This revenue figure reflects the company's market position and business performance in its industry.

Innovent Biologics has an estimated valuation of $11,204,600,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Innovent Biologics was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Innovent Biologics has approximately 501-1000 employees. The company continues to grow its workforce to support its business operations and expansion.